Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Hisamitsu Pharmaceutical Co ( (JP:4530) ) has shared an announcement.
Hisamitsu Pharmaceutical and its affiliate TAIYO KOSAN Co., Inc. announced that TAIYO KOSAN has filed an amendment to its tender offer registration statement for Hisamitsu’s common shares, share acquisition rights and American Depositary Receipts, following the expiration of the waiting period under the U.S. Hart-Scott-Rodino Antitrust Improvements Act. The amendment, submitted to Japan’s Kanto Local Finance Bureau, also revises the previously published public notice of the tender offer but does not change the purchase conditions or terms of the offer, indicating that regulatory clearance processes are progressing while the core terms of the proposed acquisition remain intact for investors and other stakeholders.
The most recent analyst rating on (JP:4530) stock is a Buy with a Yen7130.00 price target. To see the full list of analyst forecasts on Hisamitsu Pharmaceutical Co stock, see the JP:4530 Stock Forecast page.
More about Hisamitsu Pharmaceutical Co
Hisamitsu Pharmaceutical Co., Inc. is a Japanese drugmaker best known for its external pain relief and topical patch products, operating in the pharmaceutical sector with listings on the Prime Market of the Tokyo Stock Exchange, the Premier Market of the Nagoya Stock Exchange, and the Main Market of the Fukuoka Stock Exchange, reflecting a broad presence in Japan’s capital markets.
Average Trading Volume: 321,028
Technical Sentiment Signal: Buy
Current Market Cap: Yen464.2B
See more data about 4530 stock on TipRanks’ Stock Analysis page.